Thursday 7 May, 2026
Background Hydroxyurea (HU) is the standard disease-modifying therapy for sickle cell disease (SCD), improving survival and reducing vaso-occlusive complications through…
Read moreAbstracts
Isatuximab SC versus IV in patients with Relapsed/Refractory Multiple Myeloma: Insights from longitudinal PK/PD Analysis of Serum M-Protein in the non-inferiority IRAKLIA Trial
Thursday 7 May, 2026
Introduction: The subcutaneous (SC) formulation of isatuximab (Isa) combined with pomalidomide and dexamethasone (Pd) demonstrated non-inferiority to Isa intravenous (IV)…
Read moreQUANTITATIVE DIFFERENCES IN TRENDS OF INFLAMMATORY BIOMARKERS IN PREGNANT AND POSTPARTUM INDIVIDUALS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE
Thursday 7 May, 2026
Introduction: Pregnancy involves major physiological changes that can alter dynamics of biomarkers commonly used in pre-pregnancy[1–3]. Among these, C-reactive protein…
Read moreTranslational Modeling Based on a Semi-Mechanistic Target-Mediated Drug Disposition (TMDD) Approach
Thursday 7 May, 2026
Objectives: ABO21009 is a humanized IgG1 monoclonal antibody targeting human CD45RC, currently developed for the treatment of rheumatoid arthritis. The…
Read moreImpact of soluble BCMA on the PKPD assessment and dose selection for BCMA 4-1BBL
Thursday 7 May, 2026
Introduction: BCMA 4-1BBL is a costimulatory molecule designed to enhance T-cell engager efficacy in multiple myeloma (MM). Its bispecific binding…
Read morePredicting Receptor Occupancy via Empirical Approximations from Nonlinear Population PK Modeling
Thursday 7 May, 2026
Objectives Assessing monoclonal antibody target engagement in vivo is critical to understanding drug activity and informing the selection of a…
Read moreMACHINE LEARNING-BASED COVARIATE SELECTION IN POPULATION PHARMACOKINETICS: A SYSTEMATIC EVALUATION OF BORUTA ALGORITHM WITH TREE-BASED METHODS AGAINST SCM+
Thursday 7 May, 2026
Introduction Stepwise covariate modeling (SCM) [1] is the most widely used method for covariate selection. An improved version (called SCM+)…
Read morePrediction of Hydroxyurea Pharmacokinetics and Dose Adjustment in Children with Mild, Moderate, and Severe Renal Impairment Using Physiologically Based Pharmacokinetic Modeling
Thursday 7 May, 2026
Background Hydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD) in pediatric populations. Kidney involvement is a recognized…
Read moreDevelopment of a physiologically-based pharmacokinetic model to characterize the drug-drug interaction of the inhaled compound CHF6001 as a victim of CYP3A4 inhibitors
Thursday 7 May, 2026
Objectives: CHF6001 is a PDE4 inhibitor that was specifically designed to be delivered via inhalation [1]. In vitro data showed…
Read moreTEZEPELUMAB POPULATION PHARMACOKINETICS SUPPORTS PAEDIATRIC EXTRAPOLATION IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)
Thursday 7 May, 2026
Introduction/Objectives: Tezepelumab (210 mg subcutaneously [SC] every 4 weeks [Q4W]) is approved in several markets worldwide as an add-on maintenance…
Read more